Most Read Articles
25 Feb 2021
The standard combination therapy against paediatric migraine—consisting of a combination of parenteral medications—appears to yield moderate pain relief, which persists up to 1 week after administration, a new study has found.
Natalia Reoutova, 5 days ago

The phase III OPTIMUM (Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis) study shows that ponesimod is superior to teriflunomide in reducing annualized relapse rate (ARR), fatigue, MRI activity, and brain volume loss in relapsing multiple sclerosis (RMS).

Beta-synuclein levels in CSF may spot Alzheimer’s disease early

20 Feb 2021

Enriched beta-synuclein levels in cerebrospinal fluid (CSF) may be used as a marker of synaptic degeneration in Alzheimer’s disease (AD), a study has found.

A total of 393 patients underwent a novel ELISA assay for beta-synuclein to evaluate its potential as a diagnostic and predictive marker for AD. Of the patients, 151 had AD, 18 had behavioural variant frontotemporal dementia (bvFTD), 46 had Parkinson syndrome, 23 had Creutzfeldt-Jakob disease (CJD), and 29 had amyotrophic lateral sclerosis (ALS, n=29). The remaining patients served as disease control (n=66) and non-neurodegenerative control (n=60).

Assay results were examined against core AD biomarkers (ie, total tau, phospho-tau, and amyloid-β peptide 1–42). The coexistence of beta-synuclein with vesicular glutamate transporter 1 (VGLUT1) was also determined, and beta-synuclein levels were quantified in brain homogenates.

Beta-synuclein levels measured using the newly established ELISA showed a strong correlation with antibody-free quantitative mass spectrometry data (p<0.0001). Specifically, CSF beta-synuclein levels were elevated in AD-mild cognitive impairment (p<0.0001), AD dementia (p<0.0001), and CJD (p<0.0001), but not in bvFTD, Parkinson syndrome, or ALS.

Moreover, beta-synuclein concentration was found in VGLUT1-positive glutamatergic synapses, and its expression was significantly diminished in brain tissue from patients with AD (p<0.01).

Synaptic loss plays a crucial role in AD, and the present data demonstrate a sensitive and robust ELISA assay for the measurement of brain-enriched beta-synuclein, which is localized in glutamatergic synapses. Mass spectrometry-based observations of elevated beta-synuclein levels in CSF may be therefore used as a marker of synaptic degeneration.

Editor's Recommendations
Most Read Articles
25 Feb 2021
The standard combination therapy against paediatric migraine—consisting of a combination of parenteral medications—appears to yield moderate pain relief, which persists up to 1 week after administration, a new study has found.
Natalia Reoutova, 5 days ago

The phase III OPTIMUM (Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis) study shows that ponesimod is superior to teriflunomide in reducing annualized relapse rate (ARR), fatigue, MRI activity, and brain volume loss in relapsing multiple sclerosis (RMS).